Clinical Trial Update: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating eribulin plus standard chemotherapy versus standard chemotherapy alone for metastatic urothelial carcinoma, with the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Eribulin (Halaven) (eribulin mesylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING